Morgan Stanley assumed coverage of SI-Bone (SIBN) with an Overweight rating and a price target of $15, down from $19. The firm’s lower target factors in some of the overhang around the recently disclosed civil investigative demand from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, but says clear adoption and new products support growth.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SIBN:
- SI-Bone price target raised to $18 from $16 at Truist
- SI-BONE Reports Strong Q3 Growth and Optimistic Outlook
- SI-Bone reports Q3 EPS (16c), consensus (24c)
- SI-Bone narrows FY24 revenue view to $165M-$166M from $165M-$167M
- SIBN Earnings this Week: How Will it Perform?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
